Laboratory Corp. of America (NYSE:LH) issued an update on its FY 2020
Pre-Market earnings guidance on Thursday morning. The company provided EPS guidance of 11.75-12.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $11.98. The company issued revenue guidance of $12.012-12.243 billion, compared to the consensus revenue estimate of $11.94 billion.Laboratory Corp. of America also updated its FY20 guidance to $11.75-$12.15 EPS.

Shares of Laboratory Corp. of America stock traded up $0.55 during trading hours on Friday, reaching $195.28. The company’s stock had a trading volume of 624,203 shares, compared to its average volume of 701,471. Laboratory Corp. of America has a one year low of $140.53 and a one year high of $196.36. The company has a market capitalization of $17.82 billion, a P/E ratio of 25.69, a P/E/G ratio of 1.81 and a beta of 1.07. The stock’s fifty day simple moving average is $176.75 and its two-hundred day simple moving average is $170.23. The company has a debt-to-equity ratio of 0.93, a quick ratio of 1.08 and a current ratio of 1.17.

Laboratory Corp. of America (NYSE:LH) last released its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.86 earnings per share for the quarter, beating analysts’ consensus estimates of $2.80 by $0.06. Laboratory Corp. of America had a net margin of 6.63% and a return on equity of 15.33%. The firm had revenue of $3 billion for the quarter, compared to analyst estimates of $2.92 billion. During the same period last year, the firm earned $2.52 earnings per share. The business’s quarterly revenue was up 7.6% compared to the same quarter last year. As a group, research analysts forecast that Laboratory Corp. of America will post 11.25 earnings per share for the current year.

Several analysts have recently commented on the stock. Citigroup increased their target price on shares of Laboratory Corp. of America from $179.00 to $204.00 and gave the company a neutral rating in a report on Friday. ValuEngine downgraded shares of Laboratory Corp. of America from a hold rating to a sell rating in a report on Tuesday, December 3rd. UBS Group lowered their target price on shares of Laboratory Corp. of America from $204.00 to $200.00 and set a buy rating for the company in a report on Monday, October 21st. Piper Sandler increased their target price on shares of Laboratory Corp. of America from to in a report on Thursday. Finally, Zacks Investment Research upgraded shares of Laboratory Corp. of America from a sell rating to a hold rating and set a $186.00 target price for the company in a report on Monday, January 13th. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus price target of $193.19.

In related news, SVP Der Vaart Sandra D. Van sold 208 shares of the firm’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $188.49, for a total transaction of $39,205.92. Following the completion of the sale, the senior vice president now owns 2,819 shares in the company, valued at $531,353.31. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Mark S. Schroeder sold 188 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $188.49, for a total transaction of $35,436.12. Following the sale, the executive vice president now owns 533 shares of the company’s stock, valued at approximately $100,465.17. The disclosure for this sale can be found here. Insiders have sold 637 shares of company stock valued at $118,502 in the last 90 days. 0.74% of the stock is currently owned by corporate insiders.

About Laboratory Corp. of America

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.

Featured Story: What is a Buy-Side Analyst?

Earnings History and Estimates for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.